TELA TELA Bio

TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development

TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development

Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options

MALVERN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ("TELA") (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue reconstruction, announced today that it has welcomed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. After 32 years as a private practice general surgeon specializing in hernia repair and abdominal wall reconstruction, Dr. Freedman has joined TELA Bio to advocate for a more natural hernia repair mesh option as an alternative to permanent and resorbable synthetic mesh.

“As a surgeon who has performed thousands of hernia repairs with plastic mesh over the past three decades, I fully understand the clinical limitations of using synthetic mesh to repair human tissue,” said Dr. Freedman. “Unfortunately, plastic mesh has the potential to create a foreign body response and inflammation in some patients, the effects of which can cause complications immediately after surgery or even many years down the road. OviTex® is a very different material and was designed specifically to reduce this foreign-body response. As I incorporated it in my practice, I saw first-hand how the careful work that went into the design positively impacted my patients.” He added, “TELA Bio is providing much needed innovation in the hernia repair specialty, and I believe this product has remarkable potential to help surgeons break decades-long dependence on plastic mesh, while advancing treatment and better serving the patient.”

In his role, Dr. Freedman will be using his extensive experience as a healthcare provider to share the clinical and financial benefits of the OviTex Reinforced Tissue Matrix portfolio with surgeons and hospital administration. “TELA Bio has spent the past several years working closely with surgeons in capturing and documenting clinical and financial evidence. They’ve got a powerful message, one I’m enthusiastic to help spread,” Dr. Freedman added.

“We are thrilled to welcome Dr. Freedman to our team. Improving patient access to our innovative technology requires education throughout the healthcare delivery system, which includes surgeons, clinical resources, supply chain, hospital administrators, and patients,” said Antony Koblish, Co-founder, President, and Chief Executive Officer, TELA Bio. “Dr. Freedman adds a credible, experienced voice that will help distinguish us from the many larger, legacy companies. Like us, he shares a passion for safer hernia repair and his decision to join our mission further reinforces the critical need to offer patients a more natural hernia repair.”

To find practicing surgeons throughout the country who believe in providing patients with a more natural hernia repair option, . 

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality, data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

About OviTex

OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see the OviTex Reinforced Tissue Matrix Instructions for Use.

The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. A surgeon must use his or her own clinical judgment when deciding which products are appropriate for treatment of a particular patient. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets.



TELA Bio Contact
Stuart Henderson
Vice President, Corporate Development and Investor Relations
TELA Bio, Inc.
484-320-2930

Investor Contact
Greg Chodaczek
347-620-7010 
 
EN
05/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE

TELA Bio Reports Second Quarter 2025 Financial Results

TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...

 PRESS RELEASE

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted ...

 PRESS RELEASE

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...

 PRESS RELEASE

TELA Bio to Announce Second Quarter 2025 Financial Results

TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...

 PRESS RELEASE

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch